Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice

American Journal of Veterinary Research

Volumn 74, Issue 5, 2013, Pages 771-778

  Scharf, Valery F ^a   Farese, James P ^a,c   Coomer, Alastair R ^a,d   Milner, Rowan J ^a   Taylor, David P ^a,e   Salute, Marc E ^a   Chang, Myron N ^b   Neal, Dan ^b   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Florida   (United States)

^c VCA Animal Care Center of Sonoma   (United States)

^d Veterinary Specialist Group   (New Zealand)

^e Laverty Pathology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DRUG MEGADOSE; HISTOLOGY; IMMUNOASSAY; KAPLAN MEIER METHOD; LOW DRUG DOSE; MICROPHOTOGRAPHY; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; OSTEOSARCOMA CELL; TUMOR XENOGRAFT;

ANIMALIA; CANIS FAMILIARIS; MUS; MUS MUSCULUS;

EID: 84877060906     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.5.771     Document Type: Article

References (56)

1. Dernell WS, Ehrhart NP, Straw RC, et al. Tumors of the skeletal system. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. St Louis: Saunders Elsevier, 2007;540-582.
2. Thomas R, Wang HJ, Tsai PC, et al. Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res 2009;17:365-377.
3. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-999.
4. Farese JP, Fox LE, Detrisac C, et al. Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. Am J Vet Res 2004;65:659-664.
5. Paoloni M, Davis S, Lana S, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics [serial online]. 2009;10:625. Available at: www.biomedcentral.com/1471-2164/10/625. Accessed Dec 1, 2010.
6. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-156.
7. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-1560.
8. Shapiro W, Fossum TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-511.
9. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
10. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200:531-533.
11. Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-2008.
12. Chun R, de LorimierLPUpdate on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract 2003;33:491-516.
13. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res 2007;27:155-164.
14. Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res 2009;335:241-248.
15. Pepper MS, Ferrara N, Orci L. Potent synergism between vascular endothelial cell growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-831.
16. Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 2011;117:4925-4938.
17. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006;368:1329-1338.
18. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK 1/2, MCL-1, ezrin pathways. Mol Cancer 2009;8:118.
19. Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745.
20. Jia SF, Guan H, Duan X, et al. VEGF165 is necessary to the metastatic potential of Fas- osteosarcoma cells but will not rescue the Fas+ cells. J Exp Ther Oncol 2008;7:89-97.
21. Mei J, Gao Y, Zhang L, et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 2008;30:29-34.
22. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
24. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
25. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
26. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145-1151.
27. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903.
28. Vistica DT, Hollingshead M, Borgel SD, et al. Therapeutic vulnerability of an in vivo model of soft part sarcoma (ASPS) to anti-angiogenic therapy. J Pediatr Hematol Oncol 2009;31:561- 570.
29. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic softtissue sarcomas. J Clin Oncol 2005;23:7135-7142.
30. US National Institutes of Health Clinical Trials. A study of bevacizumab in combination with chemotherapy for treatment of osteosarcoma. 2011. Available at: clinicaltrials.gov/ct2/show/ NCT00667342?term=osteosarcoma+bevacizumab&rank=1. Accessed Jan 17, 2011.
31. Barroga EF, Kadosawa T, Okumura M, et al. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999;61:361-367.
32. Coomer AR, Farese JP, Milner R, et al. Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. Am J Vet Res 2009;70:127-133.
33. Shi W, Teschendorf C, Muzyczka N, et al. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003;66:1-9.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
35. Kabbinavar F, Irl C, Zurlo A, et al. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008;75:215-223.
36. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
37. Presta LG, Chen C, O'Connor SH, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
38. Prichard CN, Kim S, Yazici YD, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007;117:674-679.
39. Sottnik JL, Hansen RJ, Gustafson DL, et al. Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft. Vet Comp Oncol 2011;9:118-130.
40. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining antiangiogenic (Avastin) and vascular disrupting (CA4P or OXi4503) agent therapy. Anticancer Res 2008;28:2027-2031.
41. Mori S, Ueda T, Kuratsu S, et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995;61:148-152.
42. Dutour A, Monteil J, Paraf F, et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 2005;11:311-319.
43. R&D Systems Inc. Quantikine ELISA human VEGF immunoassay. 2012. Available at: www.rndsystems.com/pdf/dve00.pdf. Accessed Feb 1, 2012.
44. Scheidegger P, Weiglhofer W, Suarez S, et al. Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol Chem 1999;380:1449-1454.
45. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
46. Lana S, U'ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant treatment of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21:764-769.
47. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-577.
48. Yang SY, Yu H, Krygier JE, et al. High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma [serial online]. 2007;2007:1-7.Available at: www. hindawi.com/journals/srcm/2007/095628/abs/. Accessed Jun 29, 2011.
49. Lin F, Zheng S, Shen Z. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol 2011;28:649-653.
50. Thamm DH, O'Brien MG, Vail DM. Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. Vet Comp Oncol 2008;6:126-132.
51. Siemann DW, Warrington KH Jr, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol 2000;57:5-12.
52. Lozonschi L, Sunamura M, Kobari M, et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252- 1258.
53. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
54. Yoon SS, Eto H, Lin CM, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251- 6256.
55. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large advanced tumors. Int J Radiat Oncol Biol Phys 2005;62:846-853.
56. London CA, Hannah AL, Zadovoskaya R, et al. Phase I doseescalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768.